Loading people...
Houman Ashrafian is the Executive Vice President and Head of Research and Development at Sanofi, based in London, United Kingdom. Prior to assuming this executive position in September 2023, he spent over a decade as a Managing Partner at SV Health Investors, where he focused on healthcare venture capital and biotechnology growth equity. He previously served as Vice President and Head of the Clinical Science Group at UCB, and maintains clinical appointments as a Visiting Professor at the University of Oxford and an Honorary Consultant Cardiologist at John Radcliffe Hospital. As a serial entrepreneur, Ashrafian has co-founded or chaired at least six biotechnology startups, including Alchemab Therapeutics, Enara Bio, and Sitryx, while also establishing four additional healthcare ventures. His career bridges clinical cardiology and life sciences investment, centering on the discovery and commercialization of transformational precision medicines.
Houman Ashrafian stands as a distinguished Managing Partner at SV Health Investors, a globally recognized venture capital firm committed to advancing healthcare through strategic investments. In his pivotal role, Dr. Ashrafian is instrumental in shaping the firm's investment strategy, particularly within the dynamic and rapidly evolving life sciences and biotechnology landscapes. His leadership helps steer SV Health Investors towards companies poised to deliver significant breakthroughs in patient care and medical science.
Dr. Ashrafian's investment focus is broad yet deeply specialized, encompassing areas such as novel therapeutics, advanced diagnostics, medical devices, and transformative digital health solutions. He is particularly passionate about identifying opportunities where cutting-edge scientific research can be translated into tangible, impactful products and services for patients worldwide. His approach is characterized by a rigorous scientific evaluation combined with a keen understanding of market needs and regulatory pathways, ensuring that investments are not only innovative but also commercially viable and clinically relevant.
Prior to his tenure at SV Health Investors, Houman Ashrafian built an impressive career spanning both academia and industry, providing him with a unique vantage point in healthcare investment. A medical doctor by training, he holds an MD from the University of Oxford, where he also served as a Professor of Medicine. This academic background instilled in him a profound appreciation for scientific discovery and clinical excellence. His industry experience includes significant roles at major pharmaceutical companies, such as GSK, where he gained invaluable insights into drug development, clinical trials, and commercialization strategies. This diverse background equips him with the expertise to evaluate complex scientific propositions and guide early-stage companies through critical development phases.
At SV Health Investors, Dr. Ashrafian leverages his extensive network and deep domain knowledge to support portfolio companies in achieving their full potential. He works closely with entrepreneurs and management teams, offering strategic guidance on everything from R&D pipelines and clinical development to market access and team building. His commitment extends beyond capital provision; he acts as a true partner, fostering innovation and driving the growth of companies that are set to redefine the future of health.
His contributions reinforce SV Health Investors' reputation as a leader in healthcare venture capital, a firm dedicated to backing visionary founders and disruptive technologies. Houman Ashrafian's leadership ensures that SV Health Investors continues to be at the forefront of investing in solutions that address unmet medical needs and improve global health outcomes.
Houman Ashrafian is a Managing Partner at SV Health Investors, a leading venture capital firm focused on healthcare. He is renowned for his expertise in identifying and nurturing innovative companies within the life sciences and biotechnology sectors.
He primarily invests in groundbreaking companies across the life sciences, biotechnology, digital health, and broader healthcare sectors. His focus is on novel therapeutics, advanced diagnostics, medical devices, and solutions that significantly improve patient outcomes.
Houman Ashrafian works as a Managing Partner at SV Health Investors, a prominent venture capital firm specializing in healthcare investments globally.
